busulfan has been researched along with Acute Lymphoid Leukemia in 111 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination." | 9.15 | Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus (TAC) and short-course methotrexate in 36 patients, TAC and sirolimus in 3, and TAC and mycophenolate mofetil in 5." | 9.15 | Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. ( Alsina, M; Anasetti, C; Ayala, E; Di Nicola, M; Fernandez, H; Field, T; Janssen, W; Kharfan-Dabaja, MA; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Santarone, S, 2011) |
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 9.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| "In patients with acute myelogenous leukemia, the leukemia-free survival and regimen-related toxicity rates obtained in our study appear similar to those achieved with other preparative regimens, including those containing Cy and total body irradiation (TBI)." | 7.77 | Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). ( Avalos, BR; Biggs, JC; Brodsky, I; Copelan, EA; Crilley, P; Harman, GS; Kapoor, N; Klein, JL; Szer, J; Thompson, JM, 1993) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 7.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes." | 6.82 | Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016) |
| "In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination." | 5.15 | Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus (TAC) and short-course methotrexate in 36 patients, TAC and sirolimus in 3, and TAC and mycophenolate mofetil in 5." | 5.15 | Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. ( Alsina, M; Anasetti, C; Ayala, E; Di Nicola, M; Fernandez, H; Field, T; Janssen, W; Kharfan-Dabaja, MA; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Santarone, S, 2011) |
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 5.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| "Sixteen patients with poor-prognosis acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and non-Hodgkin's lymphoma (NHL) underwent conditioning with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) (BUCY-2) plus melphalan (90 or 135 mg/m2) and autologous bone marrow transplantation (AuBMT) in a phase I study." | 5.07 | Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. ( Barnett, MJ; Chan, KW; Klingemann, HG; Lansdorp, PM; Nevill, TJ; Phillips, GL; Reece, DE; Shepherd, JD; Spinelli, JJ, 1991) |
| "In patients with acute myelogenous leukemia, the leukemia-free survival and regimen-related toxicity rates obtained in our study appear similar to those achieved with other preparative regimens, including those containing Cy and total body irradiation (TBI)." | 3.77 | Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). ( Avalos, BR; Biggs, JC; Brodsky, I; Copelan, EA; Crilley, P; Harman, GS; Kapoor, N; Klein, JL; Szer, J; Thompson, JM, 1993) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 3.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| " Graft-versus-host disease (GVHD) prophylaxis included methotrexate, cyclosporine A, and rabbit antithymocyte globulin (Thymoglobulin)." | 3.74 | Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. ( Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR, 2007) |
| "Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes." | 2.82 | Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016) |
| "Comparing patients with acute myeloid leukemia/myelodysplastic syndrome versus those with acute lymphoblastic leukemia/bi-phenotypic leukemia, the 1-year overall and leukemia-free survival rates were 75±10% versus 50±13%, respectively (P=0." | 2.79 | Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. ( Bilger, K; Blaise, D; Chevallier, P; de La Tour, RP; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Socié, G; Tabrizi, R; Vigouroux, S, 2014) |
| "Stomatitis was the most frequent toxicity in both trials." | 2.78 | Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. ( Forman, S; Liu, A; Palmer, J; Radany, E; Rosenthal, J; Schultheiss, T; Somlo, G; Stein, A; Wong, JY, 2013) |
| " busulfan combined with fludarabine and analyzed the outcomes." | 2.77 | Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ( Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ, 2012) |
| " busulfan (Bu) in combination with clofarabine (Clo) in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation (SCT)." | 2.77 | Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. ( Alousi, A; Andersson, BS; Basset, R; Champlin, RE; Ciurea, S; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Ledesma, C; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Shpall, EJ, 2012) |
| "BU used to treat patients with acute lymphoblastic leukemia (ALL)." | 2.76 | Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia. ( Chen, YB; Hu, J; Shen, ZX; Tang, W; Wang, L; Zhao, WL, 2011) |
| " BU, given as four single daily doses of 150 mg/m2, is appropriate and safe in all age groups of children." | 2.71 | Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages. ( Berry, A; Earl, JW; Nath, C; Shaw, PJ, 2004) |
| "Relapses were similar in both arms." | 2.71 | Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. ( Aplenc, R; Bunin, N; Cnaan, A; Kamani, N; Shaw, K; Simms, S, 2003) |
| "Twelve children with high-risk acute lymphoblastic leukemia underwent stem cell transplantation (SCT) with a conditioning regimen consisting of busulfan, cyclophosphamide and thiotepa." | 2.70 | [Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia]. ( Adachi, S; Akiyama, Y; Kubota, M; Lin, YW; Nakahata, T; Umeda, K; Usami, I; Watanabe, K, 2001) |
| "Thiotepa (TTP) is an alkylating agent that has been used mainly in breast and ovarian cancer with 20-50% response rates." | 2.69 | The role of thiotepa in autologous bone marrow transplantation for acute leukemia. ( Finlander, R; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G, 1998) |
| "Busulfan has been previously only available in an oral formulation due to its poor water solubility." | 2.69 | A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. ( Apperley, J; Craddock, C; Eades, A; Goldman, J; Hassan, M; Kanfer, E; Matthews, J; Nilsson, C; Olavarria, E; Timms, A, 2000) |
| "Leukemic recurrence was observed in eight patients." | 2.68 | Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle. ( Bernaudin, F; Cornu, G; Demeocq, F; Donadieu, J; Esperou-Bourdeau, H; Mechinaud-Lacroix, F; Michel, G; Sadoun, A; Souillet, G; von Bueltzingsloewen, A, 1995) |
| " Administration of busulfan as crushed rather than whole tablets reduced the delay time for appearance of busulfan in plasma but had no effect on absorption or other pharmacokinetic parameters." | 2.67 | Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. ( Brian, RJ; Earl, JW; Scharping, CE; Shaw, PJ, 1994) |
| "Etoposide has also been tested in a wide range of combination regimens, but for many of these combinations, relatively few patients are included, and some combinations have only been tested in patients who have undergone autologous transplants." | 2.48 | High-dose etoposide in allogeneic stem cell transplantation. ( Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH, 2012) |
| "The technique of high-dose chemotherapy and bone-marrow transplantation takes advantage of any potential dose-response effect in the treatment of cancer and the ability of infused marrow to circumvent severe myelotoxicity." | 2.38 | High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report. ( Boyd, AW; Brodie, GN; Green, MD; Griffiths, JD; McGrath, KM; Russell, DM; Scarlett, JD; Sheridan, WP; Thomas, RJ; Vaughan, SL, 1989) |
| "For acute lymphoblastic leukemia (ALL) patients, total body irradiation (TBI)- based conditioning regimens are the first choice specially in young population." | 1.91 | Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. ( Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z, 2023) |
| "Optimal conditioning for adults with acute lymphoblastic leukemia (ALL) treated with haploidentical hematopoietic cell transplantation (haplo-HCT) and post-transplant cyclophosphamide has not been established so far." | 1.72 | Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W ( Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A, 2022) |
| "Busulfan was administered IV and according to body weight." | 1.62 | Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. ( Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S, 2021) |
| "For patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), total body irradiation (TBI) has been particularly advocated as a part of the conditioning regimen in case of extramedullary involvement in sanctuary sites such as the central nervous system (CNS), to ensure greater tissue penetration." | 1.62 | Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous system involvement. ( Behfar, M; Enshaei, M; Esfandbod, M; Hamidieh, AA; Kabootari, M; Monzavi, SM, 2021) |
| "Among patients with acute lymphoblastic leukemia (ALL) (n = 314), there were no differences in overall survival (OS) by conditioning regimen." | 1.56 | Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. ( Atsuta, Y; Fukuda, T; Imahashi, N; Inamoto, Y; Ishikawa, J; Kako, S; Kanda, J; Kimura, T; Kobayashi, H; Kondo, E; Kozai, Y; Matsuoka, KI; Sakai, H; Tanaka, M; Terakura, S; Uchida, N, 2020) |
| "Only viral infections were significantly increased in the non-TBI group." | 1.48 | Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. ( Anagnostopoulos, A; Apostolou, C; Athanasiadou, A; Batsis, I; Bousiou, Z; Bouziana, S; Chatziioannou, K; Constantinou, V; Douka, V; Gavriilaki, E; Gianouzakos, V; Iskas, M; Lalayanni, C; Mallouri, D; Papathanasiou, M; Sakellari, I; Sotiropoulos, D; Yannaki, E, 2018) |
| "We conducted a retrospective analysis to compare outcomes in adult patients with acute lymphoblastic leukemia (ALL) who underwent allogeneic hematopoietic cell transplantation (allo-HCT) with conditioning regimens containing cyclophosphamide (CY) in combination with total body irradiation (TBI), oral busulfan (p." | 1.43 | Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. ( Atsuta, Y; Doki, N; Fukuda, T; Inoue, Y; Kako, S; Kanamori, H; Kurokawa, M; Mitsuhashi, K; Mizuta, S; Morishima, Y; Nagamura-Inoue, T; Onizuka, M; Ozawa, Y; Shigematsu, A; Takahashi, S; Tanaka, J, 2016) |
| "Outcome of children with acute lymphoblastic leukemia (ALL) has improved over the years, but not for those with multiple recurrences because of high therapy resistance and heavily pretreated history that potentially cause physical damages." | 1.43 | Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia. ( Aoki, Y; Imai, K; Ishiwata, Y; Kajiwara, M; Miyawaki, R; Mizutani, S; Morio, T; Takagi, M; Tomizawa, D; Yasuhara, M, 2016) |
| "Cataract was prospectively assessed by serial slip lamp tests in 271 patients included in the Leucémie Enfants Adolescents (LEA) programme, the French cohort of childhood leukaemia survivors." | 1.42 | Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study. ( Auquier, P; Barlogis, V; Berbis, J; Bertrand, Y; Chastagner, P; Contet, A; Galambrun, C; Horwitz, M; Kanold, J; Michel, G; Oudin, C; Plantaz, D; Poiree, M; Sirvent, N; Villes, V, 2015) |
| "This conditioning regimen of FLAG combined with L-PAM (which did not contain BU and TBI) was associated with good outcomes and minimal late adverse effects in children with acute leukemia who have undergone allogeneic BMT from unrelated volunteer donors." | 1.40 | Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. ( Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014) |
| "Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included in the current study." | 1.38 | Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy. ( Chae, YS; Choi, JY; Kang, BW; Kim, JG; Kim, YK; Lee, SJ; Lee, YJ; Moon, JH; Seo, JW; Shin, HC; Sohn, SK; Suh, JS, 2012) |
| "Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects." | 1.36 | Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. ( Amini, M; Ghavamzadeh, A; Hadjibabaie, M; Hamedani, R; Hamidieh, AA; Sadrai, S, 2010) |
| "A 21-year-old woman with acute lymphoblastic leukemia underwent bone marrow transplantation (BMT)." | 1.32 | Busulfan neurotoxicity and EEG abnormalities: a case report. ( Bonifazi, F; Cirignotta, F; Guarino, M; La Morgia, C; Mondini, S, 2004) |
| "Busulfan was quantitated using ultraviolet absorbance detection after derivatization and HPLC separation." | 1.32 | Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. ( Blazar, B; Bostrom, B; Bruns, A; Enockson, K; Johnson, A, 2003) |
| " Recent data revealed immunosuppressive characteristics and substantial haematopoietic stem cell toxicity after repeated dosing of mice." | 1.32 | Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). ( Baumgart, J; Becker, M; Fichtner, I, 2003) |
| "Death and treatment failure (relapse or death, inverse of leukemia-free survival) were more frequent in the Bu/CY group (RR, 1." | 1.31 | Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. ( Bolwell, B; Cahn, JY; Camitta, BM; Davies, SM; Gale, RP; Giralt, S; Heilmann, C; Henslee-Downey, PJ; Herzig, RH; Horowitz, MM; Hutchinson, R; Keating, A; Klein, JP; Lazarus, HM; Milone, GA; Neudorf, S; Perez, WS; Powles, RL; Prentice, HG; Ramsay, NK; Schiller, G; Socié, G; Vowels, M; Weisdorf, DJ; Wiley, J; Yeager, A, 2000) |
| "The prognosis for DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of DS acute lymphoblastic leukemia (ALL) is equal to that of non-DS ALL." | 1.31 | Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. ( Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM, 2002) |
| "Diagnoses included acute myelogenous leukemia (n = 20), acute lymphoblastic leukemia (n = 8) and chronic myelogenous leukemia (n = 2)." | 1.30 | Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. ( Kato, K; Kojima, S; Matsuyama, T, 1998) |
| "Children with acute lymphoblastic leukemia (ALL) undergoing allogeneic bone marrow transplantation (BMT) using total body irradiation (TBI)-containing conditioning regimens are at risk of substantial late sequelae affecting growth and endocrine functions." | 1.29 | Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. ( Carpenter, PA; Giri, N; Marshall, GM; Russell, SJ; Vowels, MR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (4.50) | 18.7374 |
| 1990's | 24 (21.62) | 18.2507 |
| 2000's | 23 (20.72) | 29.6817 |
| 2010's | 46 (41.44) | 24.3611 |
| 2020's | 13 (11.71) | 2.80 |
| Authors | Studies |
|---|---|
| Esfandbod, M | 2 |
| Enshaei, M | 1 |
| Monzavi, SM | 2 |
| Kabootari, M | 1 |
| Behfar, M | 3 |
| Hamidieh, AA | 4 |
| Swoboda, R | 1 |
| Labopin, M | 4 |
| Giebel, S | 2 |
| Angelucci, E | 1 |
| Arat, M | 1 |
| Aljurf, M | 1 |
| Sica, S | 1 |
| Pavlu, J | 1 |
| Socié, G | 4 |
| Bernasconi, P | 1 |
| Rigacci, L | 1 |
| Tischer, J | 1 |
| Risitano, A | 1 |
| Rovira, M | 2 |
| Saccardi, R | 1 |
| Pioltelli, P | 1 |
| Van Gorkom, G | 1 |
| Vitek, A | 1 |
| Savani, BN | 1 |
| Spyridonidis, A | 1 |
| Peric, Z | 2 |
| Nagler, A | 3 |
| Mohty, M | 4 |
| Zhang, H | 1 |
| Fan, Z | 1 |
| Huang, F | 1 |
| Han, L | 1 |
| Xu, Y | 1 |
| Xu, N | 1 |
| Deng, L | 1 |
| Wang, S | 1 |
| Lin, D | 1 |
| Luo, X | 1 |
| Zhang, Q | 1 |
| Liu, X | 1 |
| Li, X | 1 |
| Liang, X | 1 |
| Xie, S | 1 |
| Qu, H | 1 |
| Yu, S | 1 |
| Zhou, H | 1 |
| Shi, P | 1 |
| Xuan, L | 1 |
| Lin, R | 1 |
| Liu, H | 2 |
| Jin, H | 1 |
| Sun, J | 1 |
| Liu, Q | 1 |
| Banet, A | 1 |
| Bazarbachi, A | 1 |
| Stocker, N | 1 |
| Duléry, R | 1 |
| Malard, F | 1 |
| Van de Wyngaert, Z | 1 |
| Genthon, A | 1 |
| Memoli, M | 1 |
| Legrand, O | 1 |
| Bonnin, A | 1 |
| Ledraa, T | 1 |
| Belhocine, R | 1 |
| Sestili, S | 1 |
| El-Cheikh, J | 2 |
| Brissot, E | 1 |
| Rehman, MEU | 1 |
| Chattaraj, A | 1 |
| Mahboob, A | 1 |
| Ijaz, Z | 1 |
| Franco, D | 1 |
| Farhan, M | 1 |
| Dharma, K | 1 |
| Mumtaz, H | 1 |
| Saeed, S | 1 |
| Basit, J | 1 |
| Aslam, MM | 1 |
| Iftikhar, A | 1 |
| Faraz, F | 1 |
| Anwer, F | 1 |
| Yu, ZP | 1 |
| Ding, JH | 1 |
| Sun, AN | 1 |
| Chen, BA | 1 |
| Ge, Z | 1 |
| Wu, DP | 1 |
| Peczynski, C | 1 |
| Polge, E | 1 |
| Cornelissen, J | 1 |
| Carpenter, B | 1 |
| Potter, M | 1 |
| Malladi, R | 1 |
| Byrne, J | 1 |
| Schouten, H | 1 |
| Fegueux, N | 1 |
| Kuball, J | 1 |
| Gilleece, M | 1 |
| Imahashi, N | 1 |
| Terakura, S | 1 |
| Kondo, E | 1 |
| Kako, S | 3 |
| Uchida, N | 2 |
| Kobayashi, H | 1 |
| Inamoto, Y | 1 |
| Sakai, H | 1 |
| Tanaka, M | 1 |
| Ishikawa, J | 1 |
| Kozai, Y | 1 |
| Matsuoka, KI | 1 |
| Kimura, T | 1 |
| Fukuda, T | 3 |
| Atsuta, Y | 4 |
| Kanda, J | 1 |
| Lee, SS | 1 |
| Jung, SH | 1 |
| Do, YR | 1 |
| Kim, DS | 1 |
| Lee, JH | 3 |
| Park, HS | 1 |
| Moon, JH | 2 |
| Yi, JH | 1 |
| Park, Y | 1 |
| Koh, Y | 1 |
| Yhim, HY | 1 |
| Choi, Y | 1 |
| Mun, YC | 1 |
| Lee, WS | 2 |
| Lee, S | 1 |
| Yang, DH | 1 |
| Abdelaty, MM | 1 |
| Gawaly, A | 1 |
| Fathy, GM | 1 |
| Kabbash, I | 1 |
| Taha, A | 1 |
| Peters, C | 3 |
| Dalle, JH | 2 |
| Locatelli, F | 2 |
| Poetschger, U | 1 |
| Sedlacek, P | 1 |
| Buechner, J | 1 |
| Shaw, PJ | 3 |
| Staciuk, R | 1 |
| Ifversen, M | 1 |
| Pichler, H | 1 |
| Vettenranta, K | 1 |
| Svec, P | 1 |
| Aleinikova, O | 1 |
| Stein, J | 1 |
| Güngör, T | 1 |
| Toporski, J | 2 |
| Truong, TH | 1 |
| Diaz-de-Heredia, C | 1 |
| Bierings, M | 1 |
| Ariffin, H | 1 |
| Essa, M | 1 |
| Burkhardt, B | 1 |
| Schultz, K | 1 |
| Meisel, R | 1 |
| Lankester, A | 2 |
| Ansari, M | 1 |
| Schrappe, M | 1 |
| von Stackelberg, A | 1 |
| Balduzzi, A | 1 |
| Corbacioglu, S | 1 |
| Bader, P | 1 |
| Yalcin, K | 1 |
| Pehlivan, B | 1 |
| Celen, S | 1 |
| Bas, EG | 1 |
| Kabakci, C | 1 |
| Pashayev, D | 1 |
| Daloglu, H | 1 |
| Zhumatayev, S | 1 |
| Uygun, V | 1 |
| Karasu, GT | 1 |
| Hazar, V | 1 |
| Yesilipek, A | 1 |
| Wang, YH | 1 |
| Tien, FM | 1 |
| Tsai, CH | 1 |
| Huang, HH | 1 |
| Liu, JH | 1 |
| Liao, XW | 1 |
| Tang, JL | 1 |
| Yao, M | 1 |
| Ko, BS | 1 |
| Kaboutari, M | 1 |
| Kawamura, K | 1 |
| Mizuta, S | 2 |
| Ishiyama, K | 1 |
| Aoki, J | 1 |
| Yano, S | 1 |
| Ozawa, Y | 2 |
| Eto, T | 1 |
| Iwato, K | 1 |
| Kanamori, H | 2 |
| Kahata, K | 1 |
| Kondo, T | 1 |
| Sawa, M | 1 |
| Ichinohe, T | 1 |
| Kanda, Y | 1 |
| Kebriaei, P | 3 |
| Anasetti, C | 3 |
| Zhang, MJ | 1 |
| Wang, HL | 1 |
| Aldoss, I | 1 |
| de Lima, M | 3 |
| Khoury, HJ | 2 |
| Sandmaier, BM | 1 |
| Horowitz, MM | 2 |
| Artz, A | 1 |
| Bejanyan, N | 1 |
| Ciurea, S | 2 |
| Lazarus, HM | 3 |
| Gale, RP | 3 |
| Litzow, M | 1 |
| Bredeson, C | 1 |
| Seftel, MD | 2 |
| Pulsipher, MA | 1 |
| Boelens, JJ | 1 |
| Alvarnas, J | 1 |
| Champlin, R | 1 |
| Forman, S | 2 |
| Pullarkat, V | 1 |
| Weisdorf, D | 1 |
| Marks, DI | 2 |
| Sakellari, I | 1 |
| Gavriilaki, E | 1 |
| Chatziioannou, K | 1 |
| Papathanasiou, M | 1 |
| Mallouri, D | 1 |
| Batsis, I | 1 |
| Bousiou, Z | 1 |
| Bouziana, S | 1 |
| Constantinou, V | 1 |
| Douka, V | 1 |
| Apostolou, C | 1 |
| Iskas, M | 1 |
| Lalayanni, C | 1 |
| Athanasiadou, A | 1 |
| Sotiropoulos, D | 1 |
| Yannaki, E | 1 |
| Gianouzakos, V | 1 |
| Anagnostopoulos, A | 1 |
| Speziali, C | 1 |
| Daly, A | 2 |
| Abuhaleeqa, M | 1 |
| Nitta, J | 1 |
| Abou Mourad, Y | 1 |
| Paulson, K | 1 |
| Marinho-Dias, J | 1 |
| Lobo, J | 1 |
| Henrique, R | 1 |
| Baldaque, I | 1 |
| Pinho-Vaz, C | 1 |
| Regadas, L | 1 |
| Branca, R | 1 |
| Campilho, F | 1 |
| Campos, A | 1 |
| Medeiros, R | 1 |
| Sousa, H | 1 |
| Eslami Shahre Babaki, A | 1 |
| Rostami, T | 1 |
| Kasaeian, A | 1 |
| Koochakzadeh, L | 1 |
| Sharifi Aliabadi, L | 1 |
| Ghavamzadeh, A | 3 |
| Zhang, BL | 1 |
| Zhou, J | 1 |
| Lyu, TX | 1 |
| Gui, RR | 1 |
| Zu, YL | 1 |
| Yu, FK | 1 |
| Zhao, HF | 1 |
| Li, Z | 1 |
| Wang, J | 1 |
| Zhang, YL | 1 |
| Zhang, WL | 1 |
| Fu, YW | 1 |
| Wei, XD | 1 |
| Fang, BJ | 1 |
| Li, YF | 1 |
| Zhou, KS | 1 |
| Song, YP | 1 |
| Zhang, C | 1 |
| Zhu, H | 1 |
| Cui, H | 1 |
| Chang, X | 1 |
| Wang, Z | 1 |
| Eroglu, C | 1 |
| Pala, C | 1 |
| Kaynar, L | 1 |
| Yaray, K | 1 |
| Aksozen, MT | 1 |
| Bankir, M | 1 |
| Zararsız, G | 1 |
| Orhan, O | 1 |
| Gündog, M | 1 |
| Yıldız, OG | 1 |
| Eser, B | 1 |
| Cetin, M | 1 |
| Unal, A | 1 |
| Liu, DH | 1 |
| Xu, LP | 1 |
| Liu, KY | 1 |
| Wang, Y | 1 |
| Chen, H | 1 |
| Han, W | 1 |
| Zhang, XH | 1 |
| Yan, CH | 1 |
| Zhang, YY | 1 |
| Wang, JZ | 1 |
| Chen, YH | 1 |
| Wang, FR | 1 |
| Huang, XJ | 1 |
| Kunter, G | 1 |
| Perkins, JB | 1 |
| Pidala, J | 2 |
| Nishihori, T | 1 |
| Kharfan-Dabaja, MA | 2 |
| Field, T | 2 |
| Fernandez, H | 2 |
| Perez, L | 2 |
| Locke, F | 1 |
| Ayala, E | 2 |
| Tomblyn, M | 1 |
| Ochoa-Bayona, JL | 1 |
| Betts, B | 1 |
| Nieder, M | 1 |
| Kato, K | 4 |
| Yoshida, N | 1 |
| Matsumoto, K | 1 |
| Matsuyama, T | 2 |
| Bernard, F | 1 |
| Auquier, P | 3 |
| Herrmann, I | 1 |
| Contet, A | 3 |
| Poiree, M | 2 |
| Demeocq, F | 2 |
| Plantaz, D | 3 |
| Galambrun, C | 3 |
| Barlogis, V | 3 |
| Berbis, J | 3 |
| Garnier, F | 1 |
| Sirvent, N | 3 |
| Kanold, J | 3 |
| Chastagner, P | 2 |
| Chambost, H | 1 |
| Michel, G | 4 |
| Kim, JH | 1 |
| Stein, A | 2 |
| Tsai, N | 1 |
| Schultheiss, TE | 1 |
| Palmer, J | 2 |
| Liu, A | 2 |
| Rosenthal, J | 2 |
| Forman, SJ | 2 |
| Wong, JY | 2 |
| Chevallier, P | 1 |
| Tabrizi, R | 1 |
| Furst, S | 1 |
| Lioure, B | 1 |
| Guillaume, T | 1 |
| Delaunay, J | 1 |
| de La Tour, RP | 1 |
| Vigouroux, S | 1 |
| Blaise, D | 1 |
| Michallet, M | 1 |
| Bilger, K | 1 |
| Milpied, N | 1 |
| Moreau, P | 1 |
| Boztug, H | 1 |
| Zecca, M | 1 |
| Sykora, KW | 1 |
| Veys, P | 1 |
| Slatter, M | 1 |
| Skinner, R | 1 |
| Wachowiak, J | 3 |
| Pötschger, U | 1 |
| Glogova, E | 1 |
| Horwitz, M | 1 |
| Bertrand, Y | 3 |
| Villes, V | 1 |
| Oudin, C | 2 |
| Kato, M | 1 |
| Hasegawa, D | 1 |
| Koh, K | 1 |
| Takita, J | 1 |
| Inagaki, J | 1 |
| Yabe, H | 1 |
| Goto, H | 2 |
| Adachi, S | 2 |
| Hayakawa, A | 1 |
| Takeshita, Y | 1 |
| Sawada, A | 1 |
| Thouvenin, S | 1 |
| Tabone, MD | 1 |
| Lutz, P | 1 |
| Ducassou, S | 1 |
| Gandemer, V | 1 |
| Beliard, S | 1 |
| Vercasson, C | 1 |
| Baruchel, A | 1 |
| Leverger, G | 1 |
| El-Jawahri, A | 1 |
| Li, S | 1 |
| Ballen, KK | 1 |
| Cutler, C | 1 |
| Dey, BR | 1 |
| Driscoll, J | 1 |
| Hunnewell, C | 1 |
| Ho, VT | 1 |
| McAfee, SL | 1 |
| Poliquin, C | 1 |
| Saylor, M | 1 |
| Soiffer, RJ | 1 |
| Spitzer, TR | 1 |
| Alyea, E | 1 |
| Chen, YB | 2 |
| Kröger, N | 2 |
| Bornhäuser, M | 2 |
| Stelljes, M | 1 |
| Pichlmeier, U | 1 |
| Trenschel, R | 1 |
| Schmid, C | 1 |
| Arnold, R | 2 |
| Martin, H | 1 |
| Heinzelmann, M | 1 |
| Wolschke, C | 1 |
| Meyer, RG | 1 |
| Bethge, W | 1 |
| Kobbe, G | 1 |
| Ayuk, F | 2 |
| Gökbuget, N | 1 |
| Hölzer, D | 1 |
| Zander, A | 1 |
| Beelen, D | 1 |
| Aoki, Y | 1 |
| Miyawaki, R | 1 |
| Imai, K | 1 |
| Takagi, M | 1 |
| Kajiwara, M | 1 |
| Ishiwata, Y | 1 |
| Yasuhara, M | 1 |
| Morio, T | 1 |
| Mizutani, S | 1 |
| Tomizawa, D | 1 |
| Tang, B | 1 |
| Zheng, C | 1 |
| Zhu, X | 1 |
| Geng, L | 1 |
| Wang, X | 2 |
| Ding, K | 1 |
| Yao, W | 1 |
| Tong, J | 1 |
| Song, K | 1 |
| Zhang, L | 1 |
| Qiang, P | 1 |
| Zhang, X | 1 |
| Sun, Z | 1 |
| Fang, J | 1 |
| Zhang, R | 1 |
| Wang, H | 1 |
| Hong, M | 1 |
| Wu, Q | 1 |
| Nie, D | 1 |
| You, Y | 2 |
| Zhong, Z | 1 |
| Li, W | 1 |
| Hu, Y | 1 |
| Xia, L | 1 |
| Mitsuhashi, K | 1 |
| Shigematsu, A | 1 |
| Doki, N | 1 |
| Onizuka, M | 1 |
| Takahashi, S | 1 |
| Kurokawa, M | 1 |
| Inoue, Y | 1 |
| Nagamura-Inoue, T | 1 |
| Morishima, Y | 1 |
| Tanaka, J | 1 |
| Ruiz-Delgado, GJ | 1 |
| Gutiérrez-Riveroll, KI | 1 |
| Gutiérrez-Aguirre, CH | 1 |
| Gómez-Almaguer, D | 1 |
| Eyzaguirre-Zapata, R | 1 |
| Priesca-Marin, M | 1 |
| González-Carrillo, ML | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Li, QB | 1 |
| Li, L | 1 |
| Chen, ZC | 1 |
| Xia, LH | 1 |
| Zou, P | 1 |
| Wang, T | 1 |
| Pérez, WS | 2 |
| Antin, JH | 1 |
| Copelan, E | 2 |
| George, B | 1 |
| Gupta, V | 1 |
| Halter, J | 1 |
| Klumpp, TR | 1 |
| Lewis, VA | 1 |
| McCarthy, P | 1 |
| Rizzieri, DA | 1 |
| Sabloff, M | 1 |
| Szer, J | 3 |
| Tallman, MS | 1 |
| Weisdorf, DJ | 2 |
| Hamedani, R | 1 |
| Hadjibabaie, M | 1 |
| Amini, M | 1 |
| Sadrai, S | 1 |
| Nemecek, ER | 1 |
| Guthrie, KA | 1 |
| Sorror, ML | 1 |
| Wood, BL | 1 |
| Doney, KC | 1 |
| Hilger, RA | 1 |
| Scott, BL | 1 |
| Kovacsovics, TJ | 1 |
| Maziarz, RT | 1 |
| Woolfrey, AE | 1 |
| Bedalov, A | 1 |
| Sanders, JE | 1 |
| Pagel, JM | 1 |
| Sickle, EJ | 1 |
| Witherspoon, R | 1 |
| Flowers, ME | 1 |
| Appelbaum, FR | 1 |
| Deeg, HJ | 2 |
| Kalaycio, M | 1 |
| Bolwell, B | 2 |
| Rybicki, L | 1 |
| Absi, A | 1 |
| Andresen, S | 1 |
| Pohlman, B | 1 |
| Dean, R | 1 |
| Sobecks, R | 1 |
| Farag, SS | 1 |
| Wood, LL | 1 |
| Schwartz, JE | 1 |
| Srivastava, S | 1 |
| Nelson, RP | 1 |
| Robertson, MJ | 1 |
| Abonour, R | 1 |
| Secrest, A | 1 |
| Cox, E | 1 |
| Baute, J | 1 |
| Sullivan, C | 1 |
| Kane, K | 1 |
| Jones, DR | 1 |
| Nakazato, T | 1 |
| Sanada, Y | 1 |
| Mihara, A | 1 |
| Aisa, Y | 1 |
| Santarone, S | 1 |
| Di Nicola, M | 1 |
| Alsina, M | 1 |
| Janssen, W | 1 |
| Ochoa, L | 1 |
| Perkins, J | 1 |
| Raychaudhuri, J | 1 |
| Lee, KH | 1 |
| Choi, SJ | 1 |
| Kim, DY | 1 |
| Seol, M | 1 |
| Lee, YS | 1 |
| Kang, YA | 1 |
| Jeon, M | 1 |
| Yun, SC | 1 |
| Joo, YD | 1 |
| Kang, MJ | 1 |
| Kim, H | 2 |
| Park, JH | 1 |
| Bae, SH | 1 |
| Ryoo, HM | 1 |
| Kim, MK | 1 |
| Hyun, MS | 1 |
| Tang, W | 1 |
| Wang, L | 1 |
| Zhao, WL | 1 |
| Shen, ZX | 1 |
| Hu, J | 1 |
| Garming-Legert, K | 1 |
| Remberger, M | 1 |
| Ringdén, O | 1 |
| Hassan, M | 2 |
| Dahllöf, G | 1 |
| Lee, JW | 1 |
| Kang, HJ | 1 |
| Lee, SH | 1 |
| Yu, KS | 1 |
| Kim, NH | 1 |
| Yuk, YJ | 1 |
| Jang, MK | 1 |
| Han, EJ | 1 |
| Song, SH | 1 |
| Park, KD | 1 |
| Shin, HY | 1 |
| Jang, IJ | 1 |
| Ahn, HS | 1 |
| Hamidieh, A | 1 |
| Kargar, M | 1 |
| Jahani, M | 1 |
| Alimoghaddam, K | 1 |
| Bahar, B | 1 |
| Mousavi, SA | 1 |
| Iravani, M | 1 |
| Jalali, A | 1 |
| Jalili, M | 1 |
| Shin, HC | 1 |
| Lee, YJ | 1 |
| Lee, SJ | 1 |
| Kang, BW | 1 |
| Chae, YS | 1 |
| Kim, JG | 1 |
| Choi, JY | 1 |
| Seo, JW | 1 |
| Kim, YK | 1 |
| Suh, JS | 1 |
| Sohn, SK | 1 |
| Somlo, G | 1 |
| Schultheiss, T | 1 |
| Radany, E | 1 |
| Madden, T | 1 |
| Thall, PF | 1 |
| Ledesma, C | 2 |
| Shpall, EJ | 2 |
| Hosing, C | 2 |
| Qazilbash, M | 2 |
| Popat, U | 2 |
| Alousi, A | 2 |
| Nieto, Y | 2 |
| Champlin, RE | 2 |
| Jones, RB | 2 |
| Andersson, BS | 2 |
| Basset, R | 1 |
| Parmar, S | 1 |
| Khouri, I | 1 |
| Corker, E | 1 |
| Astwood, E | 1 |
| Williams, J | 1 |
| Vora, A | 1 |
| Savoie, ML | 2 |
| Geddes, M | 2 |
| Chaudhry, A | 1 |
| Stewart, D | 1 |
| Duggan, P | 1 |
| Bahlis, N | 1 |
| Storek, J | 2 |
| Brown, C | 1 |
| Shafey, M | 1 |
| Turner, AR | 2 |
| Russell, J | 1 |
| Bruserud, O | 1 |
| Reikvam, H | 1 |
| Kittang, AO | 1 |
| Ahmed, AB | 1 |
| Tvedt, TH | 1 |
| Sjo, M | 1 |
| Hatfield, KJ | 1 |
| Ussowicz, M | 1 |
| Musiał, J | 1 |
| Duszeńko, E | 1 |
| Haus, O | 1 |
| Kałwak, K | 1 |
| Bostrom, B | 1 |
| Enockson, K | 1 |
| Johnson, A | 1 |
| Bruns, A | 1 |
| Blazar, B | 1 |
| Fichtner, I | 1 |
| Becker, M | 1 |
| Baumgart, J | 1 |
| Bunin, N | 1 |
| Aplenc, R | 1 |
| Kamani, N | 1 |
| Shaw, K | 1 |
| Cnaan, A | 1 |
| Simms, S | 1 |
| Shah, AJ | 1 |
| Lenarsky, C | 1 |
| Kapoor, N | 4 |
| Crooks, GM | 1 |
| Kohn, DB | 1 |
| Parkman, R | 1 |
| Epport, K | 1 |
| Wilson, K | 1 |
| Weinberg, K | 1 |
| Nath, C | 1 |
| Berry, A | 1 |
| Earl, JW | 2 |
| La Morgia, C | 1 |
| Mondini, S | 1 |
| Guarino, M | 1 |
| Bonifazi, F | 1 |
| Cirignotta, F | 1 |
| Dai, QY | 1 |
| Souillet, G | 2 |
| Bleyzac, N | 1 |
| Manel, AM | 1 |
| Bruno, B | 1 |
| Souillet, AL | 1 |
| Homole, E | 1 |
| Pages, MP | 1 |
| Berlier, P | 1 |
| David, M | 1 |
| Berthier, JC | 1 |
| Massenavette, B | 1 |
| Contamin, B | 1 |
| Philippe, N | 1 |
| Massenkeil, G | 1 |
| Nagy, M | 1 |
| Le Coutre, P | 1 |
| Heine, F | 1 |
| Rosen, O | 1 |
| Dörken, B | 1 |
| Oyekunle, AA | 1 |
| Zabelina, T | 1 |
| Schieder, H | 1 |
| Renges, H | 1 |
| Fehse, N | 1 |
| Waschke, O | 1 |
| Fehse, B | 1 |
| Kabisch, H | 1 |
| Zander, AR | 1 |
| Small, TN | 1 |
| Young, JW | 1 |
| Castro-Malaspina, H | 1 |
| Prockop, S | 1 |
| Wilton, A | 1 |
| Heller, G | 1 |
| Boulad, F | 1 |
| Chiu, M | 1 |
| Hsu, K | 1 |
| Jakubowski, A | 1 |
| Kernan, NA | 1 |
| Perales, MA | 1 |
| O'Reilly, RJ | 1 |
| Papadopoulos, EB | 1 |
| Russell, JA | 1 |
| Balogh, A | 1 |
| Larratt, L | 1 |
| Chaudhry, MA | 1 |
| Bahlis, NJ | 1 |
| Brown, CB | 1 |
| Quinlan, D | 1 |
| Stewart, DA | 1 |
| Gesundheit, B | 1 |
| Resnick, IB | 1 |
| Rosenthal, MA | 1 |
| Grigg, AP | 1 |
| Sheridan, WP | 2 |
| Scheid, C | 1 |
| Pettengell, R | 1 |
| Ghielmini, M | 1 |
| Radford, JA | 1 |
| Morgenstern, GR | 1 |
| Stern, PL | 1 |
| Crowther, D | 1 |
| Ashihara, E | 1 |
| Shimazaki, C | 1 |
| Yamagata, N | 1 |
| Hirata, T | 1 |
| Okawa, K | 1 |
| Oku, N | 1 |
| Inaba, T | 1 |
| Fujita, N | 1 |
| Nakagawa, M | 1 |
| von Bueltzingsloewen, A | 3 |
| Bélanger, R | 2 |
| Perreault, C | 2 |
| Bonny, Y | 2 |
| Roy, DC | 2 |
| Boileau, J | 2 |
| Kassis, J | 2 |
| Lavallée, R | 2 |
| Lacombe, M | 2 |
| Gyger, M | 1 |
| Scharping, CE | 1 |
| Brian, RJ | 1 |
| O'Riordan, JM | 1 |
| FitzSimon, S | 1 |
| O'Connor, M | 1 |
| McCann, SR | 1 |
| Schrøder, H | 1 |
| Clausen, N | 1 |
| Thorling, K | 1 |
| Hokland, P | 1 |
| Copelan, EA | 3 |
| Biggs, JC | 2 |
| Thompson, JM | 2 |
| Crilley, P | 1 |
| Brodsky, I | 1 |
| Klein, JL | 2 |
| Harman, GS | 2 |
| Avalos, BR | 2 |
| Lalonde, Y | 1 |
| Mrsić, M | 1 |
| Nemet, D | 1 |
| Labar, B | 1 |
| Bogdanić, V | 1 |
| Radman, I | 1 |
| Zupancić-Salek, S | 1 |
| Kovacević-Metelko, J | 1 |
| Aurer, I | 1 |
| Maravić, N | 1 |
| Esperou-Bourdeau, H | 1 |
| Mechinaud-Lacroix, F | 1 |
| Sadoun, A | 1 |
| Bernaudin, F | 1 |
| Cornu, G | 1 |
| Donadieu, J | 1 |
| Bettoni, C | 1 |
| Lange, A | 1 |
| Malicki, J | 2 |
| Kaczmarek-Kanold, M | 1 |
| Głuszak, B | 1 |
| Suchnicki, K | 1 |
| Daszkiewicz, P | 1 |
| Ebell, W | 1 |
| Carpenter, PA | 1 |
| Marshall, GM | 1 |
| Giri, N | 1 |
| Vowels, MR | 1 |
| Russell, SJ | 1 |
| Kojima, S | 1 |
| Finlander, R | 1 |
| Or, R | 1 |
| Naparstek, E | 1 |
| Varadi, G | 1 |
| Slavin, S | 1 |
| Boruczkowski, D | 1 |
| Chobot-Musiałkiewicz, U | 1 |
| Gorczyńska, E | 1 |
| Bogusławska-Jaworska, J | 1 |
| Słociak, M | 1 |
| Davies, SM | 1 |
| Ramsay, NK | 1 |
| Klein, JP | 2 |
| Cahn, JY | 1 |
| Camitta, BM | 1 |
| Giralt, S | 1 |
| Heilmann, C | 1 |
| Henslee-Downey, PJ | 1 |
| Herzig, RH | 1 |
| Hutchinson, R | 1 |
| Keating, A | 1 |
| Milone, GA | 1 |
| Neudorf, S | 1 |
| Powles, RL | 1 |
| Prentice, HG | 1 |
| Schiller, G | 1 |
| Vowels, M | 2 |
| Wiley, J | 1 |
| Yeager, A | 1 |
| Granados, E | 1 |
| de La Cámara, R | 1 |
| Madero, L | 1 |
| Díaz, MA | 1 |
| Martín-Regueira, P | 1 |
| Steegmann, JL | 1 |
| Arranz, R | 1 |
| Figuera, A | 1 |
| Fernández-Rañada, JM | 1 |
| Olavarria, E | 1 |
| Eades, A | 1 |
| Nilsson, C | 1 |
| Timms, A | 1 |
| Matthews, J | 1 |
| Craddock, C | 1 |
| Kanfer, E | 1 |
| Apperley, J | 1 |
| Goldman, J | 1 |
| Bieri, S | 1 |
| Helg, C | 1 |
| Chapuis, B | 1 |
| Miralbell, R | 1 |
| Schuler, US | 1 |
| Renner, UD | 1 |
| Kroschinsky, F | 1 |
| Johne, C | 1 |
| Jenke, A | 1 |
| Naumann, R | 1 |
| Ehninger, G | 1 |
| Umeda, K | 1 |
| Lin, YW | 1 |
| Watanabe, K | 1 |
| Usami, I | 1 |
| Akiyama, Y | 1 |
| Kubota, M | 1 |
| Nakahata, T | 1 |
| Zwaan, CM | 1 |
| Kaspers, GJ | 1 |
| Pieters, R | 1 |
| Hählen, K | 1 |
| Janka-Schaub, GE | 1 |
| van Zantwijk, CH | 1 |
| Huismans, DR | 1 |
| de Vries, E | 1 |
| Rots, MG | 1 |
| Peters, GJ | 1 |
| Jansen, G | 1 |
| Creutzig, U | 1 |
| Veerman, AJ | 1 |
| Bordigoni, P | 1 |
| Turello, R | 1 |
| Clement, L | 1 |
| Lascombes, P | 1 |
| Leheup, B | 1 |
| Galloy, MA | 1 |
| Plenat, F | 1 |
| Russell, S | 1 |
| Essell, JH | 1 |
| Halvorson, RD | 1 |
| Snyder, MJ | 1 |
| Johnson, RA | 1 |
| Rubinsak, JR | 1 |
| Emminger, W | 1 |
| Emminger-Schmidmeier, W | 1 |
| Haas, OA | 1 |
| Urban, C | 1 |
| Ambros, P | 1 |
| Mann, G | 1 |
| Fink, FM | 1 |
| Ferstl, G | 1 |
| Höcker, P | 1 |
| Cunningham, I | 1 |
| Atkinson, K | 1 |
| Downs, K | 1 |
| Wingard, JR | 1 |
| Plotnick, LP | 1 |
| Freemer, CS | 1 |
| Zahurak, M | 1 |
| Piantadosi, S | 1 |
| Miller, DF | 1 |
| Vriesendorp, HM | 1 |
| Yeager, AM | 1 |
| Santos, GW | 1 |
| Phillips, GL | 1 |
| Shepherd, JD | 1 |
| Barnett, MJ | 1 |
| Lansdorp, PM | 1 |
| Klingemann, HG | 1 |
| Spinelli, JJ | 1 |
| Nevill, TJ | 1 |
| Chan, KW | 1 |
| Reece, DE | 1 |
| Cao, DC | 1 |
| Tutschka, PJ | 2 |
| Wiktor-Jedrzejczak, W | 1 |
| Szczylik, C | 1 |
| Matej, H | 1 |
| Pojda, Z | 1 |
| Ratajczak, MZ | 1 |
| Myc, A | 1 |
| Siekierzyński, M | 1 |
| Kansy, J | 1 |
| Kłos, M | 1 |
| Rybicki, Z | 1 |
| Rizzoli, U | 1 |
| Mangoni, L | 1 |
| Carella, AM | 1 |
| Aglietta, M | 1 |
| Porcellini, A | 2 |
| Coleselli, P | 1 |
| Angrilli, F | 1 |
| Alessandrino, EP | 1 |
| Madon, E | 1 |
| Manna, A | 1 |
| Moretti, L | 1 |
| Carotenuto, M | 1 |
| Greco, MM | 1 |
| Bodenizza, C | 1 |
| Boyd, AW | 1 |
| Green, MD | 1 |
| Russell, DM | 1 |
| Thomas, RJ | 1 |
| McGrath, KM | 1 |
| Vaughan, SL | 1 |
| Scarlett, JD | 1 |
| Griffiths, JD | 1 |
| Brodie, GN | 1 |
| Murcek, M | 1 |
| Theil, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation[NCT02670252] | Phase 3 | 550 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia[NCT01949129] | Phase 2/Phase 3 | 1,000 participants (Anticipated) | Interventional | 2013-04-30 | Recruiting | ||
| A Phase II Open-label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantatio[NCT00863148] | Phase 2 | 30 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Allogeneic Stem Cell Transplantation With Treosulfan, VP-16 and Cyclophosphamide for Patients With Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-containing Conditioning Regimen: A Phase II-study[NCT00682305] | Phase 2 | 50 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies[NCT00627666] | Phase 2 | 52 participants (Anticipated) | Interventional | 2003-01-31 | Completed | ||
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant[NCT01366612] | Phase 3 | 53 participants (Actual) | Interventional | 2010-06-16 | Terminated (stopped due to Lack of Accrual) | ||
| PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia[NCT00494897] | Phase 4 | 374 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457] | Phase 2 | 19 participants (Actual) | Interventional | 2013-08-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01366612)
Timeframe: 1 year
| Intervention | Percent (Number) |
|---|---|
| Group 1 | 38.9 |
| Group 2 | 18.8 |
Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment | 63.2 |
4 reviews available for busulfan and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Total Body Irradiation Versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell | 2023 |
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chem | 2012 |
Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda | 1993 |
High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamid | 1989 |
33 trials available for busulfan and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell | 2023 |
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Chil | 2021 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Ch | 2014 |
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Arabinonucleosides; Busulfan; Clofarabine; D | 2014 |
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Busulfan; Chronic Disease; Clofarabine; Female | 2016 |
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).
Topics: Adolescent; Adult; Allografts; Busulfan; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; | 2015 |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2011 |
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucle | 2011 |
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Foll | 2011 |
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfa | 2011 |
Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disea | 2011 |
Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Transplant | 2012 |
Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modality Ther | 2013 |
Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Busulfan; Drug Therapy, Combination; Female; | 2013 |
Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busu | 2012 |
Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cord Blood Stem C | 2003 |
Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Disease-Free Survival; Drug Administ | 2004 |
Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytarabine; Female; Graf | 2004 |
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2007 |
High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protoco | 1994 |
Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia.
Topics: Administration, Oral; Adolescent; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, | 1994 |
Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda | 1993 |
Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclop | 1993 |
Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cause of Deat | 1995 |
Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therap | 1995 |
The role of thiotepa in autologous bone marrow transplantation for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1998 |
Early post-BMT liver function in children with acute leukemia conditioned for allo-BMT with Busulfan-containing and with FTBI-containing preparative regimens.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Humans; Immunosuppressiv | 1998 |
A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation.
Topics: Acute Disease; Adult; Busulfan; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cyc | 2000 |
[Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 2001 |
Busulphan, cyclophosphamide, and melphalan as conditioning therapy in allogeneic bone marrow transplants for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft | 1992 |
Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.
Topics: Actuarial Analysis; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Follow-U | 1992 |
Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati | 1991 |
Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission. The experience of the Italian study group.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Drug | 1989 |
75 other studies available for busulfan and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous system involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Diseases; Co | 2021 |
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, M | 2022 |
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2023 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2019 |
Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2020 |
Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies.
Topics: Busulfan; Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Hematopoietic Stem Cell Trans | 2020 |
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem | 2020 |
Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2020 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 2021 |
Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2022 |
Outcome Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia Treated with Total Body Irradiation-Free Allogeneic Hematopoietic Stem Cell Transplantation: Comparison of Patients with and Without Central Nervous System Involvement.
Topics: Adolescent; Busulfan; Central Nervous System Neoplasms; Child; Child, Preschool; Cross-Sectional Stu | 2017 |
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acu | 2017 |
Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.
Topics: Administration, Intravenous; Adolescent; Adult; Allografts; Busulfan; Disease-Free Survival; Female; | 2018 |
Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
Topics: Adult; Age Factors; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Gr | 2018 |
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Thera | 2019 |
Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Epstein-Barr Virus Infection | 2018 |
A Single-Center Experience With Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: A Modest Pitch for Non-Total Body Irradiation Conditioning Regimens.
Topics: Adolescent; Age Factors; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease Progression; D | 2019 |
Efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation in treatment of 71 children with leukemia.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Female; Hematopoietic | 2019 |
Successful pregnancy and childbirth in a patient with acute lymphoblastic leukaemia after busulfan-based myeloablative conditioning allogeneic haematopoietic stem cell transplantation: a case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Female; Hematopoietic Stem Cell Transplantation; | 2020 |
Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide | 2013 |
Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohor | 2013 |
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Hos | 2014 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 2014 |
Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.
Topics: Adolescent; Busulfan; Cataract; Child; Child, Preschool; Female; Follow-Up Studies; Growth Disorders | 2014 |
Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Diarr | 2015 |
Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study.
Topics: Adolescent; Adult; Busulfan; Cataract; Combined Modality Therapy; Dose Fractionation, Radiation; Dos | 2015 |
Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cel
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 2015 |
Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2015 |
Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia.
Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Arabinonucl | 2016 |
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclopho | 2016 |
Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide | 2016 |
Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.
Topics: Adolescent; Adult; Aged; Busulfan; Chemoradiotherapy; Cyclophosphamide; Female; Hematopoietic Stem C | 2016 |
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting.
Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Don | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combine | 2009 |
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
Topics: Adolescent; Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoies | 2010 |
Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Dose-Response | 2010 |
BU- vs TBI-based conditioning for adult patients with ALL.
Topics: Adult; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precurs | 2011 |
Intravenous busulfan-induced reversible leukoencephalopathy syndrome.
Topics: Adult; Busulfan; Fatal Outcome; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukoence | 2011 |
Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.
Topics: Adolescent; Age Factors; Anemia, Aplastic; Area Under Curve; Busulfan; Cyclophosphamide; Dose Fracti | 2011 |
The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free | 2012 |
Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.
Topics: Adolescent; Adult; Busulfan; Chi-Square Distribution; Disease-Free Survival; Drug Therapy, Combinati | 2012 |
Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; H | 2012 |
Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities.
Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busu | 2012 |
Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia; Busulfan; Child, Preschool; H | 2013 |
Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation.
Topics: Adolescent; Adult; Area Under Curve; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; | 2003 |
Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).
Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Busulfan; Cyclophosphamide; Dose-Response R | 2003 |
Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 2004 |
Busulfan neurotoxicity and EEG abnormalities: a case report.
Topics: Acute Disease; Adult; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Electroencephalograp | 2004 |
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follo | 2004 |
Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Topics: Adolescent; Adult; Blast Crisis; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free S | 2006 |
Should patients with acute lymphoblastic leukemia receive hematopoietic stem-cell transplant from an unrelated donor?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Disease-Free Survi | 2005 |
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cy | 2007 |
Regurgitation of esophageal mucosa.
Topics: Adult; Busulfan; Esophagitis; Esophagus; Hematopoietic Stem Cell Transplantation; Humans; Male; Muco | 2007 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; | 1995 |
Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis.
Topics: Acute Disease; Adolescent; Adult; Blood Component Transfusion; Busulfan; Combined Modality Therapy; | 1994 |
Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1993 |
Retinal microvascular changes following bone marrow transplantation: the role of cyclosporine.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; F | 1994 |
[Autologous bone marrow transplantation in children with malignant diseases. Bone marrow harvest and procedure-related toxicity].
Topics: Adolescent; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Cryopreservation; Cyc | 1993 |
Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
Topics: Adult; Busulfan; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Female; | 1993 |
Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1996 |
Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1998 |
High-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in children with high-risk NHL and ALL-preliminary results.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo | 1998 |
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 2000 |
Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Presc | 2000 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 2001 |
Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; | 2001 |
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; | 2002 |
Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases.
Topics: Actuarial Analysis; Acute Disease; Bone Neoplasms; Busulfan; Child; Child, Preschool; Cranial Irradi | 2002 |
Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
Topics: Bone Marrow Transplantation; Busulfan; Child, Preschool; Combined Modality Therapy; Cyclophosphamide | 1992 |
Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow T | 1992 |
Growth in children after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Height; Bone Marrow Transplantation; Busulfan; | 1992 |
Bone marrow transplantation for leukemia after conditioning with busulfan and cyclophosphamide. Bone marrow morphology in the early recovery phase.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla | 1991 |
Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulfan and cyclophosphamide. First results.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; | 1989 |
Busulfan and cyclophosphamide as conditioning regimen for autologous BMT in acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; | 1989 |
Marrow transplantation following busulfan and cyclophosphamide as treatment for translocation (4;11) acute leukaemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamid | 1988 |